Semaglutide to prevent type 2 diabetes in women with early diabetes risk after pregnancy diabetes: plan for a Belgian double-blind placebo-controlled trial

The 'SERENA' study evaluates the efficacy and safety of semaglutide for preventing type 2 diabetes in women with postpartum pre-diabetes after gestational diabetes.

• Women with postpartum pre-diabetes are at high risk for developing type 2 diabetes.
• Lifestyle interventions in the early postpartum period are often challenging and have limited effectiveness.
• There is a need for effective preventive strategies, including potential medical therapies, for this population.
• The study focuses on assessing not only efficacy and safety but also the cost-effectiveness of semaglutide.

Simplified